Literature DB >> 10795599

Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria.

G Ackermann1, R Schaumann, B Pless, M C Claros, E J Goldstein, A C Rodloff.   

Abstract

The antimicrobial activity of moxifloxacin and seven other antibiotics (four of them quinolones) against 292 strains of obligately anaerobic bacteria was assessed employing a broth microdilution technique performed in Wilkens-Chalgren broth. MIC50/MIC90 values (mg/l) for moxifloxacin were as follows: Bacteroides fragilis (n = 62) 0.25/2, Bacteroides ovatus (n = 70) 1/4, Bacteroides vulgatus (n = 29) 0.25/1, Bacteroides thetaiotaomicron (n = 17) 2/2, Bacteroides caccae (n = 11) 1/2, Prevotella spp. (n = 11) 0.25/2, Fusobacterium spp. (n = 17) 1/4, Bilophila wadsworthia (n = 29) 0.5/1, and Clostridium spp. (n = 29) 0.125/0.5, respectively. MIC50 values (mg/l) for Bacteroides distasonis (n = 8) and Peptostreptococcus spp. (n = 9) were 0.25. The results indicated that moxifloxacin was almost as active as trovafloxacin, as active as gatifloxacin, and more active than levofloxacin and ciprofloxacin against the anaerobes tested.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10795599     DOI: 10.1007/s100960050465

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  20 in total

Review 1.  In vitro antibacterial activity and pharmacodynamics of new quinolones.

Authors:  A Dalhoff; F-J Schmitz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-04-01       Impact factor: 3.267

2.  In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections.

Authors:  Ellie J C Goldstein; Diane M Citron; Yumi A Warren; Kerin L Tyrrell; C Vreni Merriam; Helen Fernandez
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

3.  Clinical and microbiological efficacy of moxifloxacin versus amoxicillin/clavulanic acid in severe odontogenic abscesses: a pilot study.

Authors:  B Al-Nawas; C Walter; T Morbach; N Seitner; E Siegel; M Maeurer; F Krummenauer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-07-29       Impact factor: 3.267

4.  Relapse of posttraumatic osteomyelitis due to Clostridium celerecrescens.

Authors:  A Mischnik; S Zimmermann; I Bekeredjian-Ding; M Egermann
Journal:  Infection       Date:  2011-06-07       Impact factor: 3.553

5.  Efficacy and safety of moxifloxacin in hospitalized patients with secondary peritonitis: pooled analysis of four randomized phase III trials.

Authors:  Jan J De Waele; Jose M Tellado; Günter Weiss; Jeffrey Alder; Frank Kruesmann; Pierre Arvis; Tajamul Hussain; Joseph S Solomkin
Journal:  Surg Infect (Larchmt)       Date:  2014-05-15       Impact factor: 2.150

Review 6.  A critical review of the fluoroquinolones: focus on respiratory infections.

Authors:  George G Zhanel; Kelly Ennis; Lavern Vercaigne; Andrew Walkty; Alfred S Gin; John Embil; Heather Smith; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

7.  Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species.

Authors:  K E Aldridge; D Ashcraft; K Cambre; C L Pierson; S G Jenkins; J E Rosenblatt
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

8.  Antimicrobial susceptibilities of Peptostreptococcus anaerobius and the newly described Peptostreptococcus stomatis isolated from various human sources.

Authors:  Eija Könönen; Anne Bryk; Päivi Niemi; Arja Kanervo-Nordström
Journal:  Antimicrob Agents Chemother       Date:  2007-04-02       Impact factor: 5.191

Review 9.  Moxifloxacin: a review of its use in the management of bacterial infections.

Authors:  Gillian M Keating; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  In vitro activities of a new des-fluoro(6) quinolone, garenoxacin, against clinical anaerobic bacteria.

Authors:  A Liebetrau; A C Rodloff; J Behra-Miellet; L Dubreuil
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.